Author + information
- Tuo Zhang,
- Shiqun Sun,
- Linghong Shen and
- Ben He
Contrast-induced acute kidney injury (CI-AKI) is typically defined by an increase in serum creatinine (SCr) after intravascular administration of contrast medium (CM). Since creatinine is an unreliable indicator for acute changes in kidney function, an early biomarker for CI-AKI diagnosis is important for initiating therapy. Recent study demonstrated that circulating microRNA-210 (miR-210) was up-regulated in AKI patients. We assessed the hypothesis that circulating miR-210 could be served as potential biomarker to early detect CI-AKI.
In preliminary study, time course of the change of miR-210 in circulation was tested in 9 patients receiving primary PCI. By TaqMan quantitative RT-PCR analysis, circulating miR-210 was peaked around 4h and decreased at 8-24 h post CM exposure. We then observed the level of circulating miR-210 at baseline and 4-6h post CM exposure in 71 patients with CI-AKI and 71 matched control without CI-AKI. CI-AKI was defined by absolute increase in SCr ≥0.3 mg/dL or relative increase in SCr ≥25% or relative increase in Cystatin C ≥10% over baseline.
The level of circulating miR-210 was significantly elevated post CM exposure in patients with CI-AKI comparing with matched control (Fold change: 3.95±0.09 vs. 0.77±0.01, p<0.001). Receiver operating characteristic analysis showed that miR-210 significantly delineated patient with CI-AKI from those without CI-AKI (Area under curve: 0.810[0.739-0.881]) with a 65.71% sensitivity and 90% specificity. Moreover, the changes of miR-210 was associated with Mehran score (Correlation coefficient: 0.327, p<0.05).
Circulating miR-210 significantly delineated patient with CI-AKI from those without CI-AKI. MiR-210 is a potential biomarker to early detect CI-AKI.